CLN-049

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
60 patients (estimated)
Sponsors
Cullinan Therapeutics Inc.
Tags
Adoptive Cellular Therapy, Tyrosine Kinase (TK) Inhibitor, CD3, FLT3
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1616
NCT Identifier
NCT05143996

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.